bioAffinity Technologies (BIAF) Net Income towards Common Stockholders (2021 - 2026)
bioAffinity Technologies (BIAF) posted quarterly Net Income towards Common Stockholders of -$3.6 million for Q1 2026, down 36.47% year-over-year from -$5.7 million in Q1 2025, and down 15.72% quarter-over-quarter from -$3.1 million in Q4 2025.
bioAffinity Technologies (BIAF) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
bioAffinity Technologies (BIAF) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$3.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 36.47% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$15.9 million (down 63.06% YoY), while the FY2025 annual figure was -$14.9 million, down 64.93% from the prior year.
- Net Income towards Common Stockholders retreated to -$3.6 million in Q1 2026 per BIAF's latest filing, from -$3.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$88052.0 in Q2 2022 and bottomed at -$5.1 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$2.6 million across 5 years, with a median of -$2.3 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 69.97% — and 2023, when it slumped 1876.3%.
- bioAffinity Technologies' Net Income towards Common Stockholders stood at -$1.7 million in 2022, then tumbled by 41.72% to -$2.4 million in 2023, then retreated by 25.02% to -$3.0 million in 2024, then retreated by 5.75% to -$3.1 million in 2025, then slipped by 15.72% to -$3.6 million in 2026.
- Business Quant data shows BIAF's Net Income towards Common Stockholders at -$3.6 million in Q1 2026, -$3.1 million in Q4 2025, and -$5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 338.41 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 339.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 241.00 Mn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -85.11 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 207.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 232.90 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 324.00 Mn |
| 10 | bioAffinity Technologies | 2.38 Mn | -721,990.64 | - | -3.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.63 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -5.05 Mn |
| Jun 30, 2025 | -4.06 Mn |
| Mar 31, 2025 | -2.66 Mn |
| Dec 31, 2024 | -2.97 Mn |
| Sep 30, 2024 | -2.00 Mn |
| Jun 30, 2024 | -2.11 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Dec 31, 2023 | -2.37 Mn |
| Sep 30, 2023 | -2.29 Mn |
| Jun 30, 2023 | -1.74 Mn |
| Mar 31, 2023 | -1.53 Mn |
| Dec 31, 2022 | -1.67 Mn |
| Sep 30, 2022 | -4.92 Mn |
| Jun 30, 2022 | -88,052.00 |
| Mar 31, 2022 | -1.47 Mn |
| Dec 31, 2021 | -5.58 Mn |
| Sep 30, 2021 | -1.51 Mn |